NYSE - Nasdaq Real Time Price USD
Thermo Fisher Scientific Inc. (TMO)
At close: November 15 at 4:00 PM EST
After hours: November 15 at 7:41 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
42,370,000.00
42,857,000.00
44,915,000.00
39,211,000.00
32,218,000.00
Cost of Revenue
25,097,000.00
25,757,000.00
25,944,000.00
19,573,000.00
16,214,000.00
Gross Profit
17,273,000.00
17,100,000.00
18,971,000.00
19,638,000.00
16,004,000.00
Operating Expense
9,867,000.00
9,782,000.00
10,464,000.00
9,413,000.00
8,111,000.00
Operating Income
7,406,000.00
7,318,000.00
8,507,000.00
10,225,000.00
7,893,000.00
Net Non Operating Interest Income Expense
-303,000.00
-496,000.00
-454,000.00
-493,000.00
-488,000.00
Other Income Expense
-266,000.00
-524,000.00
-218,000.00
-891,000.00
-175,000.00
Pretax Income
6,836,000.00
6,298,000.00
7,835,000.00
8,841,000.00
7,230,000.00
Tax Provision
640,000.00
284,000.00
703,000.00
1,109,000.00
850,000.00
Earnings from Equity Interest Net of Tax
-76,000.00
-59,000.00
-172,000.00
-4,000.00
-3,000.00
Net Income Common Stockholders
6,135,000.00
5,995,000.00
6,950,000.00
7,725,000.00
6,375,000.00
Diluted NI Available to Com Stockholders
6,135,000.00
5,995,000.00
6,950,000.00
7,725,000.00
6,375,000.00
Basic EPS
16.00
15.52
17.75
19.62
16.09
Diluted EPS
15.95
15.45
17.63
19.46
15.96
Basic Average Shares
383,000.00
386,000.00
392,000.00
394,000.00
396,000.00
Diluted Average Shares
384,250.00
388,000.00
394,000.00
397,000.00
399,000.00
Total Operating Income as Reported
7,175,000.00
6,859,000.00
8,393,000.00
10,028,000.00
7,794,000.00
Total Expenses
34,964,000.00
35,539,000.00
36,408,000.00
28,986,000.00
24,325,000.00
Net Income from Continuing & Discontinued Operation
6,135,000.00
5,995,000.00
6,950,000.00
7,725,000.00
6,375,000.00
Normalized Income
6,344,373.32
6,433,345.00
7,053,740.00
7,897,375.00
6,462,318.00
Interest Income
1,160,000.00
879,000.00
272,000.00
43,000.00
65,000.00
Interest Expense
1,463,000.00
1,375,000.00
726,000.00
536,000.00
553,000.00
Net Interest Income
-303,000.00
-496,000.00
-454,000.00
-493,000.00
-488,000.00
EBIT
8,299,000.00
7,673,000.00
8,561,000.00
9,377,000.00
7,783,000.00
EBITDA
11,504,000.00
11,079,000.00
11,942,000.00
11,969,000.00
10,108,000.00
Reconciled Cost of Revenue
25,097,000.00
25,757,000.00
25,944,000.00
19,573,000.00
16,214,000.00
Reconciled Depreciation
3,205,000.00
3,406,000.00
3,381,000.00
2,592,000.00
2,325,000.00
Net Income from Continuing Operation Net Minority Interest
6,135,000.00
5,995,000.00
6,950,000.00
7,725,000.00
6,375,000.00
Total Unusual Items Excluding Goodwill
-231,000.00
-459,000.00
-114,000.00
-197,000.00
-99,000.00
Total Unusual Items
-231,000.00
-459,000.00
-114,000.00
-197,000.00
-99,000.00
Normalized EBITDA
11,735,000.00
11,538,000.00
12,056,000.00
12,166,000.00
10,207,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-21,626.68
-20,655.00
-10,260.00
-24,625.00
-11,682.00
12/31/2020 - 3/17/1980
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
DHR Danaher Corporation
230.50
-3.71%
MEDP Medpace Holdings, Inc.
310.63
-7.23%
MYNZ Mainz Biomed N.V.
0.2387
-4.52%
ILMN Illumina, Inc.
135.05
-5.05%
IDXX IDEXX Laboratories, Inc.
420.91
-0.65%
A Agilent Technologies, Inc.
127.07
-2.42%
MTD Mettler-Toledo International Inc.
1,179.58
-4.70%
IQV IQVIA Holdings Inc.
192.68
-5.06%
WAT Waters Corporation
358.46
-4.85%
NTRA Natera, Inc.
146.06
-3.34%